Screener
Tarsus Pharmaceuticals, Inc. TARS Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Tarsus Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Tarsus Pharmaceuticals, Inc.’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:25 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001819790-26-000064
FAQ
- What is Tarsus Pharmaceuticals, Inc.'s retained earnings?
- Tarsus Pharmaceuticals, Inc. (TARS) reported retained earnings of -$452.15M in Q2 2026.
- How has Tarsus Pharmaceuticals, Inc.'s retained earnings changed year-over-year?
- Tarsus Pharmaceuticals, Inc.'s retained earnings decreased by 11.5% year-over-year, from -$405.67M to -$452.15M.
- What is the long-term trend for Tarsus Pharmaceuticals, Inc.'s retained earnings?
- Over 5 years (2020 to 2025), Tarsus Pharmaceuticals, Inc.'s retained earnings has grown at a 67.0% compound annual growth rate (CAGR), from -$32.85M to -$426.63M.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Tarsus Pharmaceuticals, Inc.'s retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude